VICM
PopularA citrullinated and matrix metalloproteinase-degraded fragment of vimentin, enabling non-invasive monitoring of macrophage-driven inflammation and tissue remodeling across autoimmune and fibrotic diseases.
Key features and values
- Detects a specific neo-epitope of vimentin modified by citrullination and matrix metalloproteinase activity.
- Reflects macrophage activation and inflammatory tissue remodeling processes.
- Provides a non-invasive measure of disease activity in conditions such as rheumatoid arthritis, Crohn’s disease, and liver fibrosis.
- Enables early assessment of therapeutic response to anti-inflammatory treatments, including anti-TNFα agents.
- Correlates with clinical indicators of disease progression and severity.
- Supports patient stratification and monitoring in clinical and translational research.
- Complements other extracellular matrix biomarkers for a comprehensive evaluation of inflammatory and fibrotic activity.
Description
The VICM biomarker assay quantifies a specific fragment of vimentin that has undergone citrullination and degradation by matrix metalloproteinases, serving as an indicator of macrophage-driven inflammation and tissue remodeling. This non-invasive assay captures dynamic changes associated with inflammatory and fibrotic processes in various diseases, including autoimmune disorders and chronic organ fibrosis. By measuring VICM levels, researchers and clinicians can monitor disease activity, evaluate early responses to anti-inflammatory therapies, and gain insights into the underlying mechanisms of tissue remodeling. VICM serves as a valuable tool in both clinical and research settings for assessing the efficacy of therapeutic interventions and understanding disease pathology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
